acetaminophen and Pneumococcal Infections

acetaminophen has been researched along with Pneumococcal Infections in 5 studies

Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.

Pneumococcal Infections: Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.

Research

Studies (5)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Participants With Edema

Swelling at vaccination site (NCT02807623)
Timeframe: baseline, 48-72 hours, and 21- 28 days (3 points)

Participants With Erythema

Reddening of the skin at vaccination site reported as the total number of participants with erythema over the duration of the study. (NCT02807623)
Timeframe: baseline, 48- 72 hours, 21-28 days (3 points)

Lactate

A Lactate meter was used to test the exercise group for lactate readings. Two lactate tests was performed for the exercise group at Visit 1, both pre and post Influenza vaccination. The first lactate reading was taken after the blood draw.The second lactate reading was obtained from a fingerstick from the hand opposite to the vaccination arm, ideally within 3-8 minutes after the study subject completes pushups. (NCT02807623)
Timeframe: Immediately prior to Influenza vaccine and 3-8 minutes after Influenza vaccine was administered and after push-ups were completed.

Level of Pain

Level of Pain will be measured by validated pain scale, using a scale of 0 ( best, no pain) to 10 (worst, as bad as imaginable, completely interferes). (NCT02807623)
Timeframe: baseline, 48-72 hours and at 21-28 days ( 3 points )

Serologic Response - A/California/7/2009

Baseline lab specimen (visit 1, day 0, before immunization) and repeated between 21-28 days (visit 3) after immunization to measure serologic response (NCT02807623)
Timeframe: Day 0 and between 21-28 days (2 points)

Serologic Response - A/Hong Kong / 4801/2014

Baseline lab specimen (visit 1, day 0, before immunization) and repeated between 21-28 days (visit 3) after immunization to measure serologic response (NCT02807623)
Timeframe: Day 0 and between 21-28 days (2 points)

Serologic Response - B/Brisbane/60/2008

Baseline lab specimen (visit 1, day 0, before immunization) and repeated between 21-28 days (visit 3) after immunization to measure serologic response (NCT02807623)
Timeframe: Day 0 and between 21-28 days (2 points)

Serologic Response - B/Phuket/3073/2013

Baseline lab specimen (visit 1, day 0, before immunization) and repeated between 21-28 days (visit 3) after immunization to measure serologic response (NCT02807623)
Timeframe: Day 0 and between 21-28 days (2 points)

Antibody Concentrations Against Protein D (Anti-PD)

Anti-protein D (anti-PD) concentrations were presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off value of the assay was an antibody concentration ≥ 100 EL.U/mL. (NCT00950833)
Timeframe: At Month 12, one month after the second vaccine dose

Number of Subjects With Any Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. (NCT00950833)
Timeframe: Within 31 days (Days 0-30) after each vaccination

Number of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. (NCT00950833)
Timeframe: During the entire study period (from Day 0 up to Month 10 or Month 12)

Antibody Concentrations Against Protein D (Anti-PD)

Anti-protein D (anti-PD) concentrations were presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off value of the assay was an antibody concentration ≥ 100 EL.U/mL. (NCT00950833)
Timeframe: Prior to (Day 0) and 7-10 days after the first vaccine dose

Antibody Concentrations Against Vaccine Pneumococcal Cross-reactive Serotypes 6A and 19A

The vaccine pneumococcal cross-reactive serotypes 6A and 19A have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in μg/mL. The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 μg/mL. (NCT00950833)
Timeframe: At Month 12, one month after the second vaccine dose

Antibody Concentrations Against Vaccine Pneumococcal Cross-reactive Serotypes 6A and 19A

The vaccine pneumococcal cross-reactive serotypes 6A and 19A have been assessed by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs) and expressed in μg/mL. The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 μg/mL. (NCT00950833)
Timeframe: Prior to (Day 0) and 7-10 days after the first vaccine dose

Antibody Concentrations Against Vaccine Pneumococcal Serotypes

Antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) have been assessed by 22F-inhibition ELISA, presented as GMCs and expressed in μg/mL. The seropositivity cut-off value of the assay was an antibody concentration ≥ 0.05 μg/mL. (NCT00950833)
Timeframe: Prior to the first study vaccine dose (At Day 0)

Antibody Concentrations Against Vaccine Pneumococcal Serotypes

Antibody concentrations against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) have been assessed by 22F-inhibition enzyme linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (μg/mL). The seropositivity cut-off value of the assay was an antibody concentration greater than or equal to (≥) 0.05 μg/mL. (NCT00950833)
Timeframe: At 7-10 days after the first vaccine dose

Antibody Concentrations Against Vaccine Pneumococcal Serotypes

The vaccine pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F). Antibody concentrations were measured by 22F-inhibition ELISA, presented as geometric mean concentrations (GMCs), expressed in μg/mL. The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 μg/mL. (NCT00950833)
Timeframe: At Month 12, one month after the second vaccine dose

Memory B-cell Detection for Vaccine Polysaccharides (PS)

B-cell detection for the pneumococcal serotype specific polysaccharides (1, 5, 6B, 18C, 19F, 23F and C) was tabulated for a subset of subjects from each group. The results are expressed as the frequencies of antigen-specific memory B-cells within the total memory B-cell population. (NCT00950833)
Timeframe: Prior to (Day 0) and 7-10 days after the first vaccine dose

Number of Nasopharyngeal Swabs With Haemophilus Influenzae

Positive cultures of H. influenzae identified in the nasopharynx were recorded. (NCT00950833)
Timeframe: At 31-44 months of age and prior to the first vaccine dose, at 40-48 months of age

Number of Nasopharyngeal Swabs With S.Pneumoniae (Cross-reactive Serotypes)

Positive cultures of S. pneumoniae cross- reactive serotypes identified in the nasopharynx were recorded. (NCT00950833)
Timeframe: At 31-44 months of age and prior to the first vaccine dose, at 40-48 months of age

Number of Nasopharyngeal Swabs With S.Pneumoniae (Non-vaccine and Non-cross-reactive Serotypes)

Positive cultures of S. pneumoniae non- Synflorix™ vaccine, non-cross-reactive serotypes identified in the nasopharynx were recorded. (NCT00950833)
Timeframe: At 31-44 months of age and prior to the first vaccine dose, at 40-48 months of age

Number of Nasopharyngeal Swabs With Streptococcus Pneumoniae (Vaccine Serotypes)

Positive cultures of S. pneumoniae Synflorix™ vaccine serotypes identified in the nasopharynx were recorded. (NCT00950833)
Timeframe: At 31-44 months of age and prior to the first vaccine dose, at 40-48 months of age

Number of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site. This outcome measure refers only to the primed groups. (NCT00950833)
Timeframe: During the 4-day (Days 0-3) post-vaccination period

Number of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site. This outcome measure refers only to the unprimed group. (NCT00950833)
Timeframe: During the 4-day (Days 0-3) post-vaccination period following each dose and across doses

Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 fever = fever > 39.5 °C. Related = symptom assessed by the investigator as causally related to study vaccination. This outcome measure refers only to the primed groups. (NCT00950833)
Timeframe: During the 4-day (Days 0-3) post-vaccination period

Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Grade 3 fever = fever > 39.5 °C. Related = symptom assessed by the investigator as causally related to study vaccination. This outcome measure refers only to the unprimed group. (NCT00950833)
Timeframe: During the 4-day (Days 0-3) post-vaccination period following each dose and across doses

Number of Subjects With New Acquisition of H. Influenzae in Nasopharyngeal Swabs

The number of subjects with new acquisition of H. influenzae detected in nasopharyngeal swabs was recorded. (NCT00950833)
Timeframe: At 31-44 months of age and prior to the first vaccine dose, at 40-48 months of age

Number of Subjects With New Acquisition of S. Pneumoniae (Cross-reactive Serotypes) in Nasopharyngeal Swabs

The number of subjects with new acquisition of S. pneumoniae (cross-reactive serotypes) detected in nasopharyngeal swabs was recorded. (NCT00950833)
Timeframe: At 31-44 months of age and prior to the first vaccine dose, at 40-48 months of age

Number of Subjects With New Acquisition of S. Pneumoniae (Non-vaccine and Non-cross-reactive Serotypes) in Nasopharyngeal Swabs

The number of subjects with new acquisition of S. pneumoniae (non-vaccine and non-cross-reactive serotypes) detected in nasopharyngeal swabs was recorded. (NCT00950833)
Timeframe: At 31-44 months of age and prior to the first vaccine dose, at 40-48 months of age

Number of Subjects With New Acquisition of S. Pneumoniae (Vaccine Serotypes) in Nasopharyngeal Swabs

The number of subjects with new acquisition of S. pneumoniae (Synflorix™ vaccine serotypes) detected in nasopharyngeal swabs was recorded. (NCT00950833)
Timeframe: At 31-44 months of age and prior to the first vaccine dose, at 40-48 months of age

Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Cross-reactive Serotypes 6A and 19A

Seropositivity status was defined as the opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A (opsono-16A and opsono-19A) ≥ the value of 8, presented as geometric mean titers (GMTs). (NCT00950833)
Timeframe: At Month 12, one month after the second vaccine dose

Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Cross-reactive Serotypes 6A and 19A

Seropositivity status was defined as the opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A (Opsono-16A and opsono-19A) ≥ the value of 8, presented as geometric mean titers (GMTs). (NCT00950833)
Timeframe: Prior to (Day 0) and 7-10 days after the first vaccine dose

Opsonophagocytic Activity (OPA) Titers Against Vaccine Pneumococcal Serotypes

Seropositivity status was defined as the opsonophagocytic activity (OPA) against pneumococcal serotypes ≥ the value of 8, presented as geometric mean titers (GMTs). The vaccine pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Opsono-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F). (NCT00950833)
Timeframe: At Month 12, one month after the second vaccine dose

Opsonophagocytic Activity (OPA) Titers Against Vaccine Pneumococcal Serotypes

Seropositivity status was defined as the opsonophagocytic activity (OPA) against pneumococcal serotypes ≥ the value of 8, presented as geometric mean titers (GMTs). The vaccine pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Opsono-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F). (NCT00950833)
Timeframe: Prior to (Day 0) and 7-10 days after the first vaccine dose

Rabbit Complement-mediated Serum Bactericidal Activity Titers Against Neisseria Meningitidis Serogroups (rSBA-Men)

The Neisseria meningitidis serogroups assessed using rabbit complement were: A, C, W-135 and Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY), presented as geometric mean titers (GMTs). The seropositivity cut-off of the assay was an antibody titer ≥ 8. (NCT00950833)
Timeframe: At 25-36 months post-vaccination in previous 107137 (NCT00496015) study

Trials

2 trials available for acetaminophen and Pneumococcal Infections

Other Studies

3 other studies available for acetaminophen and Pneumococcal Infections